Balazs Halmos, MD, of Montefiore Albert Einstein Cancer Center, discussed the potential impact of subcutaneous amivantamab EGFR-mutated NSCLC.
Balazs Halmos, MD
Advertisement
Balazs Halmos, MD, oversees the thoracic clinical trials program of novel clinical studies at the Montefiore Albert Einstein Cancer Center.
Articles by Balazs Halmos, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma
3
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
4
SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD
5